(Q38074913)

English

Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal

scientific article published on January 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

1 reference

Europe PubMed Central

Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

object named as

Andrew Elders

3

0 references

author name string

Mary Kilonzo

1

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Jenni Hislop

2

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Cynthia Fraser

4

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Donald Bissett

5

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Samuel McClinton

6

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Graham Mowatt

7

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Luke Vale

8

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

publication date

1 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

PharmacoEconomics

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

15-24

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Renal cell carcinoma: gender difference in incidental detection and cancer-specific survival

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0006-5

21 January 2018

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0006-5

21 January 2018

Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0006-5

21 January 2018

Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0006-5

21 January 2018

Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0006-5

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0006-5

21 January 2018

Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0006-5

21 January 2018

Single technology appraisal at the UK National Institute for Health and clinical excellence: a source of evidence and analysis for decision making internationally

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0006-5

21 January 2018

Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0006-5

21 January 2018

Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0006-5

21 January 2018

Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0006-5

21 January 2018

Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0006-5

21 January 2018

Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0006-5

21 January 2018

Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0006-5

21 January 2018

Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0006-5

21 January 2018

Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0006-5

21 January 2018

Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0006-5

21 January 2018

Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0006-5

21 January 2018

Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0006-5

21 January 2018

Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23329590

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23329590

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal

1 reference

https://pubmed.ncbi.nlm.nih.gov/23329590

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic Significance of Incidental Renal Cell Carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23329590

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of two simple hazard ratio estimators based on the logrank test

1 reference

https://pubmed.ncbi.nlm.nih.gov/23329590

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization : a NICE single technology appraisal

1 reference

https://pubmed.ncbi.nlm.nih.gov/23329590

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal

1 reference

https://pubmed.ncbi.nlm.nih.gov/23329590

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal

1 reference

https://pubmed.ncbi.nlm.nih.gov/23329590

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs: a NICE single technology appraisal.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23329590

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40273-012-0006-5

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

release_ho3el5gtufevrepkmsxc2khyxe

1 reference

https://api.fatcat.wiki/v0/release/ho3el5gtufevrepkmsxc2khyxe

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38074913&oldid=2201238987"